Phaseline

Companies › Chengdu Kangnuoxing Biopharma

Chengdu Kangnuoxing Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Stapokibart–Phase 3Seasonal Allergic Rhinitis (SAR)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07678931StapokibartPhase 3Seasonal Allergic Rhinitis (SAR)ImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Galderma R&D RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) LEO Pharma AnaptysBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.